Osteoporos Int 15:1003–1008CrossRefPubMed 9. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care

population. Bone 38:922–928CrossRefPubMed 10. Gehlbach SH, Avrunin JS, Puleo E, Spaeth R (2007) Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 18:805–810CrossRefPubMed 11. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575CrossRefPubMed 12. Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate BKM120 cell line Selleck LEE011 therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585–594CrossRefPubMed 13. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517CrossRefPubMed 14. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19:1421–1429CrossRefPubMed 15. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A,

Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMed 16. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921CrossRefPubMed 17. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644CrossRefPubMed 18. Cramer JA, Amonkar MM, Hebborn A, Altman R

(2005) Compliance and persistence with bisphosphonate dosing regimens among Glutamate dehydrogenase women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–Akt inhibitor 1460CrossRefPubMed 19. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686–1694CrossRefPubMed 20. Fardellone P, Gaudin A, Cotte F, Lafuma A, Marchand C, El Hasnaoui A (2005) Comparison of the persistence of daily and weekly bisphosphonates in French female patients treated for osteoporosis. J Bone Miner Res 20:S285–S286 21. Bauss F, Schimmer RC (2006) Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag 2:3–18PubMed 22. Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs.